Donna Finch

Dr. Finch is accomplished in antibody drug discovery and development, from Target discovery and validation, in vitro and in vivo models, translational biology and early clinical development. She has over 20 years’ experience leading pharmacology and translational biology teams and developing candidate drugs across multiple disease areas, leading a number of projects from conception through to the clinic. She has been involved in several now marketed antibody drug programmes, and latterly was the Clinical lead for two projects at Clinical Phase 1 and 2. She was also an Industry Lead/Biomarker leader on large multicentre personalised medicine cohorts (COPD-MAP, RA-MAP and NOVELTY), and has a wide and varied academic network across disease areas and specialities. Dr. Finch has authored more than 30 papers and is an inventor on several patents. Dr. Finch has worked at Glaxo Group Research, Roche Bioscience, Cambridge Antibody Technology, MedImmune and AstraZeneca.

Dr. Finch holds a BSc in Pharmacology from Bristol University and a PhD in Molecular Pharmacology from Leicester University.